American excellence is rooted in our nation’s ingenuity. For 250 years, the United States has been the driving force behind medical advancements and technological breakthroughs that have reshaped industries and improved lives worldwide. Our nation’s leadership in groundbreaking discoveries is no accident. It is the product of a system designed to encourage creativity, reward risk-taking, and protect the ideas that power progress.
As we celebrate World Intellectual Property Day, we should be reminded of a simple truth: protecting IP is essential to both America’s innovative leadership and the free-market system that enables it.
Strong IP protections help ensure that tomorrow’s breakthroughs have the time, resources, and investment necessary to become reality. Without these protections, the incentives that drive invention and novelty weaken, making it more challenging to bring life-changing products to market. America's innovation framework, established by the Founding Fathers in Article I of the Constitution, has helped make the U.S. the global leader in discovery by giving Congress the authority to protect the rights of authors and inventors.
Nowhere is the power of strong IP protections more evident than in the biopharmaceutical sector. The U.S. remains the world’s leading hub for pharmaceutical R&D, accounting for 55% of global investment, significantly outpacing other developed economies. American researchers and companies are responsible for many of the cutting-edge treatments available today, delivering new therapies that have extended lives and improved patient outcomes. Patients often benefit from faster access to new therapies thanks to our research ecosystem. While these achievements underscore the strength of America’s innovation model, maintaining global leadership requires continued commitment, and it cannot be taken for granted.
The race for biotechnology leadership is intensifying. China has been investing heavily in its life science capabilities in recent years, viewing the industry as both an economic engine and a strategic priority. If the U.S. weakens the policies that have long supported its innovation sector, it risks ceding leadership to a geopolitical competitor that is actively working to challenge America’s leadership in the life sciences.
Concurrently, policymakers face mounting pressure to adopt policies that risk undermining the very system behind America’s technological leadership, threatening future developments. While these proposals may seem attractive in the short term, particularly amid rising healthcare costs, their long-term consequences would be devastating. Reducing incentives to invest in pharmaceutical research would slow the pace of scientific discovery and shrink the pipeline of future treatments. In an industry where developing a single therapy can require more than a decade of research and billions of dollars in investment, a stable policy environment is essential.
America’s innovation leadership is not guaranteed. It must be actively protected and strengthened. Strong IP protections are essential to sustaining investment in the breakthroughs of tomorrow, and preserving our free-market system ensures continued medical progress and long-term economic prosperity.
As the 250th anniversary of America’s founding approaches, this moment offers an opportunity to reflect on the system that made the U.S. the world’s innovative leader. Policymakers should recommit to strengthening our IP framework to help ensure the next 250 years of technological breakthroughs are discovered at home, benefiting patients, bolstering our free-market economy, and advancing human progress for generations to come.
Andrew Langer is the Director of CPAC’s Center for Regulatory Freedom and Executive Director of the Coalition Against Socialized Medicine.
Timothy Lee is Senior Vice President of Legal and Public Affairs at the Center for Individual Freedom.
